The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis
Open accessAbstract
Hemophagocytic lymphohistocytosis (HLH) is characterized by fulminant cytokine storm leading to multiple organ dysfunction and high mortality. HLH is classified into familial (fHLH) and into secondary (sHLH). fHLH is rare and it is due to mutations of genes encoding for perforin or excretory granules of natural killer (NK) cells of CD8-lymphocytes. sHLH is also known as macrophage activation syndrome (MAS). Macrophage activation syndrome (MAS) in adults is poorly studied. Main features are fever, hepatosplenomegaly, hepatobiliary dysfunction (HBD), coagulopathy, cytopenia of two to three cell lineages, increased triglycerides and hemophagocytosis in the bone marrow. sHLH/MAS complicates hematologic malignancies, autoimmune disorders and infections mainly of viral origin. Pathogenesis is poorly understood and it is associated with increased activation of macrophages and NK cells. An autocrine loop of interleukin (IL)-1β over-secretion leads to cytokine storm of IL-6, IL-18, ferritin, and interferon-gamma; soluble CD163 is highly increased from macrophages. The true incidence of sHLH/MAS among patients with sepsis has only been studied in the cohort of the Hellenic Sepsis Study Group. Patients meeting the Sepsis-3 criteria and who had positive HSscore or co-presence of HBD and disseminated intravascular coagulation (DIC) were classified as patients with macrophage activation-like syndrome (MALS). The frequency of MALS ranged between 3 and 4% and it was an independent entity associated with early mortality after 10 days. Ferritin was proposed as a diagnostic and surrogate biomarker. Concentrations >4,420 ng/ml were associated with diagnosis of MALS with 97.1% specificity and 98% negative predictive value. Increased ferritin was also associated with increased IL-6, IL-18, IFNγ, and sCD163 and by decreased IL-10/TNFα ratio. A drop of ferritin by 15% the first 48 h was a surrogate finding of favorable outcome. There are 10 on-going trials in adults with sHLH; two for the development of biomarkers and eight for management. Only one of them is focusing in sepsis. The acronym of the trial is PROVIDE (ClinicalTrials.gov NCT03332225) and it is a double-blind randomized clinical trial aiming to deliver to patients with septic shock treatment targeting their precise immune state. Patients diagnosed with MALS are receiving randomized treatment with placebo or the IL-1β blocker anakinra.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Palmblad, K., Schierbeck, H., Sundberg, E., Horne, A., Harris, H. E., Henter, J., Antoine, D. J., & Andersson, U. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00183 · Cited by 50
RetractedAntiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Henter, J., Horne, A., Aricó, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., McClain, K., Webb, D., Winiarski, J., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21039 · Cited by 5,386
Fardet, L., Galicier, L., Lambotte, O., Marzac, C., Aumont, C., Chahwan, D., Coppo, P., & Hejblum, G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38690 · Cited by 1,475
Interleukin-18 and IL-18 Binding Protein
Dinarello, C. A., Novick, D., Kim, S., & Kaplanski, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00289 · Cited by 938
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Opal, S. M., Fisher, C. J., Dhainaut, J.-F. A., Vincent, J.-L., Brase, R., Lowry, S. F., Sadoff, J. C., Slotman, G. J., Levy, H., Balk, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 865
Jordan, M. B., Hildeman, D., Kappler, J., & Marrack, P. (2004) · Blood · doi:10.1182/blood-2003-10-3413 · Cited by 712
Rosário, C., Zandman-Goddard, G., Meyron-Holtz, E. G., D’Cruz, D. P., & Shoenfeld, Y. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-185 · Cited by 466
Macrophage activation syndrome in the era of biologic therapy
Grom, A. A., Horne, A., & De Benedetti, F. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.179 · Cited by 448
Weiss, E. S., Girard-Guyonvarc’h, C., Holzinger, D., de Jesus, A. A., Tariq, Z., Picarsic, J., Schiffrin, E. J., Foell, D., Grom, A. A., Ammann, S., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820852 · Cited by 395
Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in mice
Behrens, E. M., Canna, S. W., Slade, K., Rao, S., Kreiger, P. A., Paessler, M., Kambayashi, T., & Koretzky, G. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43157 · Cited by 392
Miettunen, P. M., Narendran, A., Jayanthan, A., Behrens, E. M., & Cron, R. Q. (2011) · Rheumatology · doi:10.1093/rheumatology/keq218 · Cited by 284
Castillo, L., & Carcillo, J. (2009) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3181a1ae08 · Cited by 271
Carter, S. J., Tattersall, R. S., & Ramanan, A. V. (2019) · Rheumatology · doi:10.1093/rheumatology/key006 · Cited by 259
on behalf of the Hellenic Sepsis Study Group, Kyriazopoulou, E., Leventogiannis, K., Norrby-Teglund, A., Dimopoulos, G., Pantazi, A., Orfanos, S. E., Rovina, N., Tsangaris, I., Gkavogianni, T., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0930-5 · Cited by 211
Self-citationKaufman, K. M., Linghu, B., Szustakowski, J. D., Husami, A., Yang, F., Zhang, K., Filipovich, A. H., Fall, N., Harley, J. B., Nirmala, N. R., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38793 · Cited by 207
Rajasekaran, S., Kruse, K., Kovey, K., Davis, A. T., Hassan, N. E., Ndika, A. N., Zuiderveen, S., & Birmingham, J. (2014) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000078 · Cited by 198
Demirkol, D., Yildizdas, D., Bayrakci, B., Karapinar, B., Kendirli, T., Koroglu, T. F., Dursun, O., Erkek, N., Gedik, H., Citak, A., et al. (2012) · Critical Care · doi:10.1186/cc11256 · Cited by 190
Schulert, G. S., Zhang, M., Fall, N., Husami, A., Kissell, D., Hanosh, A., Zhang, K., Davis, K., Jentzen, J. M., Napolitano, L., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv550 · Cited by 170
Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years
Schram, A. M., Comstock, P., Campo, M. J., Gorovets, D. J., Mullally, A., Bodio, K., Arnason, J. E., & Berliner, N. (2015) · British Journal of Haematology · doi:10.1111/bjh.13837 · Cited by 153
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice
Girard-Guyonvarc’h, C., Palomo, J., Martin, P., Rodriguez, E., Troccaz, S., Palmer, G., & Gabay, C. (2018) · Blood · doi:10.1182/blood-2017-06-789552 · Cited by 142
Beutel, G., Wiesner, O., Eder, M., Hafer, C., Schneider, A. S., Kielstein, J. T., Kühn, C., Heim, A., Ganzenmueller, T., Kreipe, H.-H., et al. (2011) · Critical Care · doi:10.1186/cc10073 · Cited by 95
A Systemic Inflammation Mortality Risk Assessment Contingency Table for Severe Sepsis*
Carcillo, J. A., Sward, K. A., Halstead, E. S., Telford, R., Jimenez-Bacardi, A., Shakoory, B., Simon, D. W., & Hall, M. W. (2016) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001029 · Cited by 91
sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia
Colafrancesco, S., Priori, R., Alessandri, C., Astorri, E., Perricone, C., Blank, M., Agmon‐Levin, N., Shoenfeld, Y., & Valesini, G. (2014) · Immunologic Research · doi:10.1007/s12026-014-8563-7 · Cited by 83
Liu, A.-C., Yang, Y., Li, M., Jia, Y., Chen, S., Ye, S., Zeng, X., Wang, Z., Zhao, J., Liu, X., et al. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3625-6 · Cited by 78
Kumar, B., Aleem, S., Saleh, H., Petts, J., & Ballas, Z. K. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0439-x · Cited by 73
Hemophagocytic Lymphohistiocytosis in Intensive Care Unit
Barba, T., Maucort‐Boulch, D., Iwaz, J., Bohé, J., Ninet, J., Hot, A., Lega, J., Guérin, C., Argaud, L., Broussolle, C., et al. (2015) · Medicine · doi:10.1097/md.0000000000002318 · Cited by 65
Ruscitti, P., Cipriani, P., Benedetto, P. D., Liakouli, V., Berardicurti, O., Carubbi, F., Ciccia, F., Guggino, G., Triolo, G., & Giacomelli, R. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13057 · Cited by 53
Brisse, E., Imbrechts, M., Put, K., Avau, A., Mitera, T., Berghmans, N., Rutgeerts, O., Waer, M., Ninivaggi, M., Kelchtermans, H., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501035 · Cited by 50
Sakumura, N., Shimizu, M., Mizuta, M., Inoue, N., Nakagishi, Y., & Yachie, A. (2018) · Cytokine · doi:10.1016/j.cyto.2018.05.017 · Cited by 44
Gormezano, N. W. S., Otsuzi, C. I., Barros, D. L., da Silva, M. A., Pereira, R. M. R., Campos, L. M. A., Borba, E. F., Bonfá, E., & Silva, C. A. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.10.015 · Cited by 41
Signoff, J. K., Fitzgerald, J. C., Teachey, D. T., Balamuth, F., & Weiss, S. L. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001507 · Cited by 34
Late Peaks of HMGB1 and Sepsis Outcome: Evidence For Synergy With Chronic Inflammatory Disorders
Karakike, E., Adami, M., Lada, M., Gkavogianni, T., Koutelidakis, I. M., Bauer, M. W., Giamarellos‐Bourboulis, E. J., & Tsangaris, I. (2018) · Shock · doi:10.1097/shk.0000000000001265 · Cited by 34
Self-citationHemophagocytic Lymphohistiocytosis Masquerading as Acute Liver Failure: A Single Center Experience
Jagtap, N., Sharma, M., Rajesh, G., Rao, P. N., Sekaran, A., Tandan, M., Ramchandani, M. J., & Reddy, D. N. (2017) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2017.01.119 · Cited by 29
Cited by
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
van der Poll, T., Shankar-Hari, M., & Wiersinga, W. J. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.012 · Cited by 1,010
Toniati, P., Piva, S., Cattalini, M., Garrafa, E., Regola, F., Castelli, F., Franceschini, F., Airò, P., Bazzani, C., Beindorf, E.-A., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102568 · Cited by 751
Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19)
Umakanthan, S., Sahu, P., Ranade, A. V., Bukelo, M. M., Rao, J. S., Abrahao-Machado, L. F., Dahal, S., Kumar, H., & KV, D. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138234 · Cited by 717
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Metadata
- Authors
- Karakike, E., & Giamarellos-Bourboulis, E. J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-01-31
- Volume
- 10
- Pages
- 55-55
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2911371912
- Cited by
- 304
- References
- 35
- FWCI
- 28.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.